Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.75), $0.07 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.28 million versus the consensus estimate of $14.91 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Sandisk (SNDK) call put ratio 1.6 calls to 1 put as share price up 8.2%
• Derya Arms Signs Collaboration Agreement with Olympic Medalist Yusuf Dikec